Opinion
Video
Author(s):
Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.
PASI and QoL: A New Approach to Treatment Goals
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
Biologics Targeting IL-12, IL-23, and IL-17 Reduce Serious Infections in Older Adults with Psoriatic Disease
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
Long-Term Safety and Efficacy of Ixekizumab in Japanese Patients with Psoriasis
Post Hoc Analysis Highlights Zasocitinib’s Efficacy Across Patient Groups